# DESCRIPTION

## FIELD OF THE INVENTION

- relate to therapeutic compositions and methods for inducing an immune response to HSV-2

## BACKGROUND OF THE INVENTION

- introduce HSV-2 and its effects
- describe HSV-2 pathogenesis
- discuss innate and adaptive immune responses to HSV-2
- summarize current vaccine formulations against HSV-2
- highlight limitations of current vaccine formulations
- discuss codon optimization based on immune response preference
- provide background on previous inventions

## SUMMARY OF THE INVENTION

- introduce the invention and its surprising discovery
- describe the construct system and its components
- outline the method of treating HSV-2 infection
- discuss the advantages of the invention
- provide examples of the invention
- describe the pharmaceutical composition and its administration
- outline the use of the construct system for treating HSV-2 infection

## DETAILED DESCRIPTION OF THE INVENTION

### I. Definitions

- define technical terms
- introduce articles "a" and "an"
- define "about"
- define "administration concurrently"
- define "simultaneously"
- define "contemporaneously"
- define "separately"
- define "sequentially"
- define "and/or"
- define "antigen" and "epitope"
- define "between"
- define "cis-acting sequence"
- define "comprise"
- define "coding sequence"
- define immune response
- define immunogenic
- define include and including
- define mammal
- define operably connected
- define open reading frame
- define initiation and termination codons
- define pharmaceutically-acceptable carrier
- define polynucleotide and nucleic acid
- define polypeptide, peptide, and protein
- define polypeptide variant and variant
- define promoter
- define sequence identity
- define similarity
- define synthetic coding sequence
- define vector

### 2. Abbreviations

- define abbreviations

### 3. HSV gD2 Coding Sequences

- introduce HSV gD2 polypeptides
- describe codon optimization
- provide example of codon-optimized sequence
- describe method of codon optimization
- provide example of modified sequence
- describe removal of signal peptide and transmembrane domain regions
- provide example of synthetic coding sequence
- describe parent HSV gD2 coding sequence
- describe variant polypeptides
- define conservative amino acid substitutions
- describe classification of amino acids
- provide tables of amino acid substitutions
- describe methods of substituting codons

### 4. Synthetic Constructs

- define regulatory nucleic acids
- describe transcriptional and translational control sequences
- list examples of promoters
- discuss enhancer elements
- describe 3′ non-translated sequences
- introduce selectable marker genes
- discuss expression of protein-encoding polynucleotides
- describe chimeric antigen-coding gene sequences
- introduce protein adjuvants and protein-destabilising elements
- discuss detoxified mutants of bacterial ADP-ribosylating toxins
- describe protein-destabilising elements
- introduce vectors for expression of recombinant proteins
- describe features of vectors for DNA vaccines
- introduce antibiotic-free selection using RNA selection markers
- describe RNA-OUT system
- describe pFAR4 and pCOR vectors
- describe pMINI vector
- introduce viral vectors
- describe retroviral vectors
- describe adenoviral vectors
- describe lentiviral vectors
- describe poxvirus vectors
- describe avipoxvirus vectors
- describe molecular conjugate vectors
- describe Alphavirus genus vectors
- describe lentiviral vectors for gene delivery
- introduce minicircle vectors

### 5. Compositions

- provide immunogenic compositions
- describe administration methods
- define pharmaceutically acceptable components
- list examples of carriers
- discuss transfection facilitating compounds
- describe cationic lipids
- provide specific examples of cationic lipids
- discuss co-lipids and their combinations
- define composition ratio of cationic lipid and co-lipid
- describe method of preparing lipid vesicles
- discuss complexing of polynucleotides with lipids
- list additional hydrophobic and amphiphilic additives
- describe particulate carriers for compositions
- discuss other particulate systems and polymers for delivery
- introduce auxiliary agents for enhancing polynucleotide entry
- list examples of auxiliary agents
- discuss adjuvants for enhancing immune response
- list examples of adjuvants
- describe poloxamers as adjuvants
- list examples of poloxamers
- describe reverse poloxamers as adjuvants
- list examples of reverse poloxamers
- discuss other commercially available poloxamers
- list examples of other poloxamers
- list poloxamers for immune response enhancement
- list auxiliary agents for immune response enhancement
- describe cytokines as adjuvants
- describe polynucleotide constructs with adjuvants
- describe GAP-DMORIE and co-lipids as adjuvants
- describe bacterial DNA as adjuvants
- describe methods of using unmethylated CpG-dinucleotides as adjuvants
- describe effects of adjuvants on immune response
- describe solubilization of nucleic acid molecules
- describe formulation of compositions
- describe preparation methods for compositions
- describe dosage and administration of compositions
- describe therapeutically effective amounts of compositions
- describe dosage schedules for compositions
- describe formulation of compositions for injection
- describe packaging and labeling of compositions
- describe routes of administration for compositions
- describe specific devices and methods for administration

## EXAMPLES

### Example 1

- construct HSV-2 DNA vaccine compositions
- describe materials and methods
- detail primer design and synthesis
- outline standard molecular biological techniques
- describe whole gene synthesis
- detail site-directed mutagenesis

### Example 3

- describe clinical study methodology
- detail HSV cell-mediated immunity

### Example 3

- describe serum sample analysis

### Example 4

- describe HSV cell-mediated immunity
- detail ELISPOT assay
- describe IFN-γ production

### Example 5

- describe delayed type hypersensitivity response
- detail analysis of injection site reactions

